Electromed (ELMD) Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Electromed in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ELMD shares.
View ELMD analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 12 month target prices for Electromed's shares. Their ELMD share price forecasts range from $15.00 to $26.00. On average, they predict the company's stock price to reach $20.50 in the next twelve months. This suggests a possible upside of 74.2% from the stock's current price.
View analysts price targets for ELMD or view top-rated stocks among Wall Street analysts.

Electromed's stock was trading at $10.4350 at the beginning of 2023. Since then, ELMD stock has increased by 12.8% and is now trading at $11.77.
View the best growth stocks for 2023 here.

Electromed saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 39,900 shares, an increase of 12.1% from the April 15th total of 35,600 shares. Based on an average trading volume of 16,000 shares, the days-to-cover ratio is presently 2.5 days. Currently, 0.6% of the shares of the company are sold short.
View Electromed's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our ELMD earnings forecast.

Electromed, Inc. (NYSEAMERICAN:ELMD) announced its quarterly earnings results on Tuesday, November, 9th. The medical equipment provider reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.06 by $0.01. The medical equipment provider had revenue of $10 million for the quarter, compared to analyst estimates of $9 million. Electromed had a net margin of 5.50% and a trailing twelve-month return on equity of 7.18%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Electromed investors own include AbbVie (ABBV), AT&T (T), ACADIA Pharmaceuticals (ACAD), CRISPR Therapeutics (CRSP), Enphase Energy (ENPH), Inseego (INSG), Novavax (NVAX), NVIDIA (NVDA) and Pfizer (PFE).

Electromed trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ELMD."

Electromed's stock is owned by a number of retail and institutional investors. Top institutional investors include Punch & Associates Investment Management Inc. (4.91%), Dimensional Fund Advisors LP (3.27%), Hunter Associates Investment Management LLC (0.86%), Renaissance Technologies LLC (0.63%), Annex Advisory Services LLC (0.27%) and BlackRock Inc. (0.22%). Insiders that own company stock include A Jones Lee, Michael Joseph Maccourt and Stephen H Craney.
View institutional ownership trends.

Shares of ELMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ELMD stock can currently be purchased for approximately $11.77.

Electromed (NYSEAMERICAN:ELMD) has a market capitalization of $100.75 million and generates $41.66 million in revenue each year. The medical equipment provider earns $2.31 million in net income (profit) each year or $0.28 on an earnings per share basis.

The company employs 132 workers across the globe.

Electromed's mailing address is 500 6th Ave NW, NEW PRAGUE, MN 56071-1134, United States. The official website for the company is smartvest.com. The medical equipment provider can be reached via phone at (952) 758-9299, via email at investorrelations@electromed.com, or via fax at 866-758-5077.